Meeting
2017 ASCO Annual Meeting
Pharmacogenetics revisits bevacizumab in breast cancer patients: An ancillary analysis of the UCBG trial COMET— A French multicentric prospective study from R&D UNICANCER.
Authors
Gerard A. Milano
Oncopharmacology Unit, Centre Antoine Lacassagne, Nice, France
Gerard A. Milano , Jean-Yves Pierga , Jocelyn Gal , Laurence Llorca , Coraline Dubot , Gilles Romieu , Isabelle Desmoulins , Etienne Brain , Anthony Goncalves , Jean-Marc Ferrero , Paul H. Cottu , Marc Debled , Olivier Tredan , Emmanuel Chamorey , Marco Carlo Merlano , Jérôme Lemonnier , Marie-Christine Etienne-Grimaldi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Other Breast Cancer Subtypes
Clinical Trial Registration Number
2012-A00244-39
Citation
J Clin Oncol 35, 2017 (suppl; abstr 1079)
DOI
10.1200/JCO.2017.35.15_suppl.1079
Abstract #
1079
Poster Bd #
71
Abstract Disclosures
Similar Posters
Poster
2019 Gastrointestinal Cancers Symposium
Sunitinib in patients with pancreatic neuroendocrine tumors (panNETs): Exploratory pharmacogenomic analyses.
First Author: Nicola Fazio
Poster
2013 Gastrointestinal Cancers Symposium
Bevacizumab (BEV) continued beyond first progression in patients (pts) with metastatic colorectal cancer (mCRC) previously treated with BEV + chemotherapy (CT): Biomarker findings from ML18147.
First Author: Stefan Kubicka
Poster
2011 ASCO Annual Meeting
Association of germ-line SNPs with overall survival (OS) in pazopanib-treated patients (Pts) with advanced renal cell carcinoma (RCC).
First Author: C. Xu
Poster
2011 ASCO Annual Meeting
The predictive value of single nucleotide polymorphisms in the vascular endothelial growth factor system in patients with metastatic colorectal cancer treated with bevacizumab plus chemotherapy as first-line treatment: Results of the phase III ACT trial NCT00598156 translational study.
First Author: T. Hansen